We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+10.14%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$116M
AUM Growth
+$19.2M
Cap. Flow
+$6.28M
Cap. Flow %
5.4%
Top 10 Hldgs %
65.75%
Holding
56
New
8
Increased
9
Reduced
8
Closed
10
Avg Time Held
2.2 quarters
Top 10 Avg Time Held
2.3 quarters
Top 20 Avg Time Held
1.9 quarters

Top Buys

Rank Stock Value
1
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$9.46M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$4.24M
3
EOCN icon
Eocene Ltd. Ordinary Shares
EOCN
+$2.62M
4
ATRC icon
AtriCure
ATRC
+$2.34M
5
VXRT icon
Vaxart
VXRT
+$2.26M

Top Sells

Rank Stock Value
1
GIVN
GIVEN IMAGING LTD
GIVN
+$4.7M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.56M
3
STXS icon
Stereotaxis
STXS
+$1.74M
4
RIOT icon
Riot Platforms
RIOT
+$1.33M
5
ACHV icon
Achieve Life Sciences
ACHV
+$928K

Sector Composition

Rank Sector Weight
1 Healthcare 83.31%
2 Miscellaneous 16.52%
3 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
WINT icon
1
DELISTED
Windtree Therapeutics Inc
WINT
$12.3M 10.53%
407,053
– –
2013 Q2
3 quarters
PCYC
2
DELISTED
PHARMACYCLICS INC
PCYC
$11.1M 9.53%
110,628
+2,000
+2% +$260K
2013 Q2
3 quarters
ATRC icon
3
AtriCure
ATRC
$2.89B
$10.7M 9.23%
570,987
+114,286
+25% +$2.34M
2013 Q2
3 quarters
AMPE
4
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$10.3M 8.87%
5,419
+4,000
+282% +$9.46M
2013 Q3
2 quarters
NVDQ icon
5
DELISTED
Novadaq Technologies Inc.
NVDQ
$5.87M 5.05%
263,541
-20,500
-7% -$407K
2013 Q2
3 quarters
STXS icon
6
Stereotaxis
STXS
$106M
$5.87M 5.05%
1,726,825
-446,298
-21% -$1.74M
2013 Q2
3 quarters
PLX icon
7
Protalix BioTherapeutics
PLX
$222M
$5.4M 4.64%
117,844
– –
2013 Q2
3 quarters
PODD icon
8
Insulet
PODD
$9.58B
$5.19M 4.46%
109,418
-12,063
-10% -$534K
2013 Q2
3 quarters
NXTM
9
DELISTED
NxStage Medical Inc.
NXTM
$4.89M 4.21%
384,154
– –
2013 Q2
3 quarters
DSCI
10
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$4.88M 4.19%
384,794
+327,785
+575% +$4.24M
2013 Q2
3 quarters
VXRT icon
11
DELISTED
Vaxart
VXRT
$4.46M 3.83%
66,344
+36,599
+123% +$2.26M
2013 Q3
2 quarters
MACK icon
12
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$2.6M 2.23%
65,438
+21,912
+50% +$938K
2013 Q3
2 quarters
EOCN icon
13
Eocene Ltd. Ordinary Shares
EOCN
$3.39M
$2.32M 1.99%
+140
New +$2.62M
2014 Q1
0 quarters
BEAT icon
14
DELISTED
BioTelemetry, Inc.
BEAT
$2.18M 1.87%
215,645
– –
2013 Q2
3 quarters
BSTC
15
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.82M 1.56%
70,088
+18,396
+36% +$441K
2013 Q2
3 quarters
KERX
16
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.7M 1.46%
100,000
+56,000
+127% +$845K
2013 Q2
3 quarters
MTEM icon
17
DELISTED
Molecular Templates, Inc.
MTEM
$1.29M 1.11%
1,639
-61
-4% -$49.5K
2013 Q4
1 quarter
SPNC
18
DELISTED
Spectranetics Corp
SPNC
$1.28M 1.1%
42,162
-10,200
-19% -$279K
2013 Q2
3 quarters
XNPT
19
DELISTED
XENOPORT, INC.
XNPT
$1.14M 0.98%
220,190
+42,828
+24% +$258K
2013 Q2
3 quarters
ELOS
20
DELISTED
Syneron Medical Ltd
ELOS
$1.13M 0.97%
90,947
– –
2013 Q2
3 quarters
CRDC
21
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.05M 0.91%
105,370
-977
-0.9% -$11.2K
2013 Q2
3 quarters
UPI
22
DELISTED
UROPLASTY INC-NEW
UPI
$1.05M 0.9%
289,332
– –
2013 Q2
3 quarters
CUTR icon
23
DELISTED
Cutera, Inc.
CUTR
$992K 0.85%
88,694
– –
2013 Q2
3 quarters
JNJ icon
24
Johnson & Johnson
JNJ
$599B
$923K 0.79%
9,400
– –
2013 Q2
3 quarters
NSPR icon
25
InspireMD
NSPR
$23.4M
– –
0
– –
2013 Q2
3 quarters
1
2 3

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2014 Portfolio in Review

As of Q1 2014, DAFNA Capital Management held 56 positions worth $116M, up 20% from $97.2M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

DAFNA Capital Management deployed $6.28M of net new capital in Q1 2014, opening 8 new positions and adding to 9 existing holdings. Its largest new stake was Eocene Ltd. Ordinary Shares: 140 shares worth $2.32M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Intercept Pharmaceuticals, Inc., an estimated $2.56M trimmed.

  • DAFNA Capital Management's largest Q1 2014 buy was Eocene Ltd. Ordinary Shares: 140 shares worth $2.32M.
  • DAFNA Capital Management added most to Ampio Pharmaceuticals Inc. in Q1 2014, an estimated $9.46M increase.
  • DAFNA Capital Management's biggest Q1 2014 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $2.56M.
  • DAFNA Capital Management fully exited GIVEN IMAGING LTD in Q1 2014, selling an estimated $4.7M.
  • DAFNA Capital Management's ten largest holdings make up 66% of its $116M portfolio in Q1 2014.
  • DAFNA Capital Management opened 8 new positions and closed 10 in Q1 2014.
  • DAFNA Capital Management's portfolio value rose 20% quarter-over-quarter to $116M.

Based on DAFNA Capital Management's 13F filing for Q1 2014, filed 15 May 2014.